Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 Feb;14(2):165-73.
doi: 10.1016/0920-1211(93)90021-x.

Efficacy and safety of zonisamide: results of a multicenter study

I E Leppik  1 , L J Willmore, R W Homan, G Fromm, K J Oommen, J K Penry, J C Sackellares, D B Smith, R P Lesser, J D Wallace, et al.
Affiliations
Clinical Trial

Efficacy and safety of zonisamide: results of a multicenter study

I E Leppik et al. Epilepsy Res. 1993 Feb.

Abstract

The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historical-controlled 16-week open label, multicenter study. The median percent reduction from baseline of partial seizures was 51.8% in the fourth month of the study (baseline median = 11.5 sz/month; treatment weeks 13-16 = 5.5 sz/month). Persons completing the efficacy study successfully were eligible for a long-term safety study; 113 entered this study. Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs. Four persons (3.7%) developed kidney stones and were withdrawn from the study 250-477 days after starting ZNS. Because of the high percentage of kidney stones, development of ZNS was stopped in the United States but was continued in Japan.

PubMed Disclaimer

Publication types